Savla et al. reported the development and delivery of a tumor-targeted, pH-responsive chimera consisting of quantum dots (QD), a MUC1 aptamer, and doxorubicin (DOX), denoted as QD-MUC1-DOX, for the chemotherapy of OC. The gene discussed is MUC1; the disease is neoplasm.